AbCellera Biologics Inc. ABCL Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from AbCellera Biologics Inc.’s reported figures.
Based on trailing twelve months.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s return on equity?
- AbCellera Biologics Inc. (ABCL) reported return on equity of -14.7% in Q1 2026.
- How has AbCellera Biologics Inc.'s return on equity changed year-over-year?
- AbCellera Biologics Inc.'s return on equity increased by 5.9% year-over-year, from -15.6% to -14.7%.
- What is the long-term trend for AbCellera Biologics Inc.'s return on equity?
- Over 4 years (2020 to 2025), AbCellera Biologics Inc.'s return on equity has grown at a -15.4% compound annual growth rate (CAGR), from 28.3% to -14.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.